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Abstract
Background: So far, human antibodies with good affinity and specificity for MUC1, a transmembrane protein overexpressed
on breast cancers and ovarian carcinomas, and thus a promising target for therapy, were very difficult to generate.
Results: A human scFv antibody was isolated from an immune library derived from breast cancer patients immunised with
MUC1. The anti-MUC1 scFv reacted with tumour cells in more than 80% of 228 tissue sections of mamma carcinoma
samples, while showing very low reactivity with a large panel of non-tumour tissues. By mutagenesis and phage display,
affinity of scFvs was increased up to 500fold to 5,7610
210 M. Half-life in serum was improved from below 1 day to more
than 4 weeks and was correlated with the dimerisation tendency of the individual scFvs. The scFv bound to T47D and MCF-7
mammalian cancer cell lines were recloned into the scFv-Fc and IgG format resulting in decrease of affinity of one binder.
The IgG variants with the highest affinity were tested in mouse xenograft models using MCF-7 and OVCAR tumour cells.
However, the experiments showed no significant decrease in tumour growth or increase in the survival rates. To study the
reasons for the failure of the xenograft experiments, ADCC was analysed in vitro using MCF-7 and OVCAR3 target cells,
revealing a low ADCC, possibly due to internalisation, as detected for MCF-7 cells.
Conclusions: Antibody phage display starting with immune libraries and followed by affinity maturation is a powerful
strategy to generate high affinity human antibodies to difficult targets, in this case shown by the creation of a highly specific
antibody with subnanomolar affinity to a very small epitope consisting of four amino acids. Despite these ‘‘best in class’’
binding parameters, the therapeutic success of this antibody was prevented by the target biology.
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Introduction
In vitro selection by phage display is a powerful and proven
technology to generate antibodies [1–4] against nearly any target
[5–7], including toxins [8–10], pathogens [11–13] or haptens [14].
It has yielded therapeutic antibodies [15,16] and binders with
properties superior to conventional (animal based) methods, and of
human origin (for review see [6,17]). Phage dispay, after a
mutagenesis strategy, further allows to improve the biochemical
properties of antibodies, for example for affinity maturation
[18,19]. The availability of these methods has thoroughly affected
the validation of antibodies for therapeutic strategies, recognising a
very high affinity as a substantial property of any lead candidate.
However, the generation of very high affinity antibodies has
proven to be difficult to some promising tumour targets, thus
substantially hindering their use for cancer treatment. Despite
that, novel cancer treatment strategies became possible by using
recombinant antibodies. One blockbuster example is trastuzumab
(HerceptinH), a humanised anti-Her2 antibody used in breast
cancer treatment. This antibody blocks the overexpression of Her2
receptor which is responsible for an aggressive disease progression
combined with a poor prognosis [20]. However, since Her2 is
overexpressed only in around 20% of all breast tumours, other
tumour antigens would be urgently needed for antibody-based
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CD227, PUM or CA-15-3). MUC1 is overexpressed on 90% of
breast cancers [21,22] and other cancers, e.g. prostate cancer
[23,24]. It is a heavily O-glycosylated transmembrane protein,
which is found on the luminal surface of many epithelial cells in
duct tissue [25,26]. MUC1 has a molecular mass of more than
400 kDa [27] and consists of three domains, a 69 amino acid
cytoplasmatic domain involved in several signaling processes [28–
30], a transmembrane domain of 31 amino acids [31] and a very
large exo-domain, which is responsible for most of the molecular
mass. This domain consists mainly of a repetitive 20 amino acid
sequence, which is termed VNTR (variable number of tandem
repeats) in homology to its corresponding genetic structure
[32,33,31,34]. The number of repeats in the VNTR domain
varies between 20 and 120, with 40–80 typically found in MUC1
[33,31,35,36]. Two serine and three threonine residues are found
per repeat. The hydroxyl groups of these amino acid residues are
potential O-glycosylation sites [27] which finally results in an
oligosaccharide content of more than 50% of the molecular mass
of MUC1 [31]. The O-glycosylations found in MUC1 of normal
epithelial tissue consist of long and branched sugar structures
from the polyactosamine type containing typically 8–10 mono-
saccharide units [37–39]. This highly glycosylated MUC1 binds
water, leading to a moisturisation of the cell surface. It protects
the cell from proteolytic attacks, avoids the colonisation by
microorganisms [40,41] and regulates cell-cell and cell-extracel-
lular matrix interactions [42,43]. In tumour cells, the apical
expression of MUC1 is lost and the apolar expression leads to
MUC1 presentation over the entire cell surface [44] resulting in
an accessibility by systematically administered antibodies [45].
Some tumour associated MUC1 is sheded into the circulation
[46,47]. Most significantly, the O-glycosylation patterns found in
the VNTRs are different between tumour MUC1 and MUC1
expressed by normal epithelial cells. Instead of long and
branched sugar chains, less complex and shorter glycosylation
patterns are found in tumours [35,37,38,48,49]. These differ-
ences lead to the presentation of new epitopes on the surface of
tumour cells mainly by exposing the formerly masked peptide
backbone of MUC1 to antibodies [50]. Hence, the different
MUC1 properties allow to discriminate and to attack MUC1
positive tumour cells using antibodies specific to these cancer
specific neo-epitopes.
Several antibodies against MUC1 were developed over the last
thirty years. One of the most prominent is the murine antibody
HMFG1, which was first published in 1981 [44]. This antibody
recognizes a peptide epitope (PDTR) within the VNTR region of
the extracellular domain of MUC1. It was humanized [51] and
afterwards clinically developed by Antisoma for the treatment of
breast cancer (huHMFG1/AS1402/R1550/Therex). Another
humanised anti-MUC1 antibody (GT-MAB 2.5-GEX, formerly
PankoMab) [45,52] recognizing a glycosylated PDTR motif is
currently in a clinical phase I study.
A large panel of rodent MUC1 antibodies was investigated in
1998 in a MUC1 workshop [53] showing that most antibodies
have different fine specificities and affinities in a range from KD
=3–400 nM. In contrast, human antibodies were found to have
only low affinities [54,55].
In this study, we describe the selection of a human anti-MUC1
scFv antibody derived from a phage display immune antibody
gene library of breast cancer patients repeatedly vaccinated with
synthetic MUC1 glycopeptides. The selected binder was affinity
and stability-matured by random mutagenesis and phage display
selection, biochemically characterised, and analysed in vitro and in
vivo for anti-cancer activity.
Results
Vaccination of breast cancer patients
Six breast cancer patients were repeatedly vaccinated with a
synthetic MUC1 glycopeptide. All patients received the synthetic
15mer MUC1-glycopeptide (APDT(GalNAc)RPAPGSTAPPA)
conjugated to KLH (Keyhole limpet hemocyanin). A total of four
to eight vaccinations per patient were administered every week
and IgG and IgM antibody production against MUC1 glycopep-
tide, purified MUC1 (Breast Mucin Antigen, BMA) and KLH was
analysed by ELISA using sera of vaccinated patients (S. Kaul,
Universita ¨tsfrauenklinik Heidelberg, unpublished data). All pa-
tients developed a significant increase in both IgG and IgM titres
after vaccination. The induced serum antibodies showed strong
binding to synthetic peptides and glycopeptides representing the
VNTR region of MUC1 as well as to KLH. These antibodies did
not show any reactivity to whole human MUC1 protein, which
was purified by affinity chromatography from cells of the MUC1
overexpressing breast cancer cell line T47D.
Construction of a human antibody gene library from
blood of vaccinated breast cancer patients
Peripheral B cells were isolated from six breast cancer patients
vaccinated with synthetic MUC1 glycopeptide. The mRNA was
extracted and reverse transcribed into cDNA. The cDNA was
pooled and used as template for PCR amplification of VH and VL
genes with a specific set of oligonucleotide primers [56]. The
human scFv library was cloned in two steps. In the first step, the
pool of VH genes, amplified with IgG specific primers, were
cloned into the phagemid pSEX81 [57]. In the second step, the
VL gene segments were cloned into pSEX81 containing the VH
gene repertoire. The obtained diversities were 6.5610
5 individual
clones for the kappa sublibrary and 1.7610
6 individual clones for
the lambda sublibrary, respectively.
Selection of human anti-MUC1 scFv
Three panning rounds were performed on purified MUC1
(BMA), followed by one panning round on synthetic MUC1
glycopeptide. Forty-two out of 46 analysed clones showed the
desired binding specificity to purified MUC1 (BMA), synthetic
MUC1 glycopeptides and to a cell lysate of T47D cells, whereas
control antigens were not bound (data not shown). The phagemid
DNA of the 42 individual clones was prepared and sequencing
revealed that all 42 clones were identical. Clone IIB6 was used for
further studies. The variable domain of IIB6 heavy chain was
derived from IGHV1-2, IGHD3-10 and IGHJ4 germline gene
fragments as determined by VBASE2 (www.vbase2.org) [58]. The
lambda light chain was derived from IGLV3-21 and IGLJ3
germline gene fragments (Fig. 1).
Specificity, affinity and stability analysis of human anti-
MUC1 scFv
The specificity of the scFv fragment IIB6 was analysed by
various assays. The specific binding of the scFv antibody to the
VNTR region of tumour-associated MUC1 was confirmed by
ELISA (data not shown) and immunoblot (Fig. 2). Purified MUC1
as well as a cell lysate of T47D cells were bound by scFv IIB6
determined by immunoblot whereas a cell lysate of fibroblasts was
not bound.
The binding of IIB6 to native tumour associated MUC1 was
analysed by flow cytometry (Fig. 3). IIB6 bound human breast
cancer cell line T47D and MCF-7, but not to SKOV3. MUC1
negative HEK293T cells were not bound by IIB6.
Anti-MUC1 Antibody
PLoS ONE | www.plosone.org 2 January 2011 | Volume 6 | Issue 1 | e15921The affinity of IIB6 to the MUC1 glycopeptide was
2,3610
27 M (data not shown) and about 3,1610
27 M for the
MUC1 peptide (Tab. 1), as determined by surface plasmon
resonance (SPR).
However, the stability of scFv IIB6 was very low, with a half-life
in serum below one day at 37uC (Fig. 4A).
Immunohistochemistry
A panel of 228 breast cancer tissues with IIB6 was analysed by
immunohistochemistry (IHC). Tumour specific staining (Fig. 5)
was observed in about 80% of the different tissue samples (Tab. 2),
whereas an analysis of 272 non-tumour tissue sections revealed a
very low reactivity with normal tissue (Tab. 3).
ScFv IIB6 allowed a good discrimination of non-tumour versus
tumour cells in a large panel of breast cancer tumour tissues, but it
had a low affinity and stability. Therefore, we decided to perform
an affinity maturation of IIB6.
Affinity maturation of the IIB6
For the construction of two affinity maturation antibody gene
libraries, the DNA encoding the anti-MUC1 binder IIB6 was
amplified four times by error-prone PCR to introduce random
mutations. The resulting IIB6 library ‘‘A’’ was cloned into the
phage display vector pHAL14 [11,8,59,60]. Three off-rate
selective pannings using 1 ng, 10 ng or 100 ng MUC1/well
were performed. After three weeks, 29, 74 and 81 phage particles
were eluted, respectively. 92 clones were analysed by ELISA on
MUC1 resulting in the identification of 28 strong binders (data
not shown). All 28 binders showed different sequence mutations.
Five binders with the strongest signal in the ELISA were further
analysed (HT186-B7, -D2, -D11, -E8, -G2). A second library ‘‘B’’
was cloned by nested error-prone PCR using IIB6 to increase the
amount of mutations. Here, four panning rounds in solution,
followed by a pulldown with streptavidin beads, were performed.
184 clones from the third and fourth panning round were
analysed as described above (data not shown). Only binders with
an high ELISA signal were sequenced, resulting in three unique
binders which were further analysed (HT200-3A-C1, -3A-E2,
-3B-E10). The third panning round of the panning in solution
was repeated and a 10006fold excess of non-biotinylated MUC1
or the binder HT186-D11 from library ‘‘A’’ was used for
competition. The competition was performed for seven days at
4uC. Here, 92 clones of each competition method were analysed
by antigen ELISA (data not shown). About three times more
binders were isolated from the panning when using the antigen
MUC1 and competition with HT186-D11. The sequencing of
the best binders resulted in five unique clones which were further
analysed (HT220-M-C6, -M-D1, -M-G8, -D-G9, D-H11). An
overview about the antibody gene libraries generated is given in
table 4 and the selected affinity maturated binders are given in
table 5.
Ranking of the antibody variants
To rank the affinity matured binders, the new binders and the
original scFv IIB6 were produced in MTPs and the supernatant
was directly used for SPR (Fig. 6). This ranking combined
productivity and affinity of the binders. The association rates
revealed a faster antigen-antibody interaction of all affinity
matured binders when compared to IIB6. The scFvs HT186-B7,
-D11, -E8, -G2, HT200-3A-C1, HT220-M-D1, -M-G8 showed
much slower antigen-antibody dissociation rates. These binders
were chosen for further analysis with binder HT186-E8 being
excluded due to some unspecific cell binding determined by FACS
(data not shown).
Figure 1. Comparison of scFv amino acid sequences of IIB6 and affinity matured anti-MUC1 scFvs. Differences in amino acid sequences
are given by the corresponding amino acid in the table (single letter code). * represents a silent point mutation leading to no change in amino acid
sequence. The upper panel shows the VH alignment, the middle pannel shows the VL alignment and the bottom pannel shows the alignment of the
linker sequences between VH and VL, consisting of the N-terminal part of CH1 and the yol epitope, and the N-terminal part of CL downstream of VL.
s.a. = see above.
doi:10.1371/journal.pone.0015921.g001
Anti-MUC1 Antibody
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ELISA using IMAC purifed scFv preparations (Fig. 7). Each of the
analysed affinity matured scFvs showed an increased binding when
compared to the original scFv IIB6.
Determination of affinities by SPR
The affinities of the six scFvs which bound best to MUC1 in the
initial rating and IIB6 were determined by surface plasmon
resonance. The results are summarized in table 1. The affinities of
the affinity matured scFvs were between KD 10
29 -1 0
210 M. The
scFv with the highest affinity, HT186-D11, showed a 500 fold
affinity increase compared to IIB6.
Epitope mapping
The epitopes of the affinity matured binders were mapped by
peptide spot analysis to ensure that no epitope shift compared to
the original IIB6 occured (Fig. 8A, B). All binders, including IIB6,
bound the same four amino acid epitope RPAP.
Analysis of the dimerisation of the anti-MUC1 scFvs
To evaluate the tendency of the scFv fragments to form dimers,
immobilized metal ion affinity chromatography (IMAC) purified
scFvs were analysed by SEC (Figure 9). The original IIB6 and
HT220-M-G8 showed a strong tendency to form dimers with
approximately 50% of the scFvs being dimerised. The other scFvs
showed a strongly reduced dimerisation tendency.
Analysis of the stability of the anti-MUC1 scFvs
The stability of the anti-MUC1 scFvs was analysed by
incubation for 30 days at 37uC in PBS (Figure 4A), followed by
ELISA to determine the binding to MUC1 peptide. The stability
of HT220-M-G8 was increased in comparison to IIB6, resulting in
a half-life of about 5 days. HT186-G2 had a half-life of about 20
days. The half-life of HT186-B7, HT186-D11, HT200-3A-C1 and
HT220-M-D1 was longer than 30 days. Therefore, the stability of
IIB6 was increased from a half day to more than 30 days by the
stability and affinity maturation process.
The stability of the four best binders was further analysed in
serum reflecting the situation in vivo (Figure 4B). Here, the half-lifes
of the analysed binders were slightly shorter compared to their
respective half-lives in PBS.
Determination of the binding on MUC1 positive tumour
cells
The scFv binding to MUC1 positive tumour cells T47D, MCF-
7, SKOV3 and to MUC1 negative HEK293T cells was analysed
by FACS (Figure 3). All affinity matured variants showed an
increased binding to T47D cells, which are the tumour cells used
for the initial selection of IIB6. The binding to MCF-7 was only
slightly increased. Only HT186-D11 was binding slightly to
SKOV3 cells. HT186-B7 showed a high background on
HEK293T cells, whereas HT186-D11 and -G2 showed only a
slight background. Overall, the affinity matured binders showed
an improved binding to MUC1 positive cells.
Comparison of the scFv sequences
The scFv gene fragments of the improved variants were
sequenced (figure 1). A hotspot of mutations was identified in
VL CDR2. Numerous mutations occured in the frameworks (FR)
with highest rate found in FR2 and FR3 of VL. No mutations on
the polypeptide level were found in the CDR3 and FR4 of VH
and CDR1 of VL. Mutations were also identified in the linker
regions. The average number of mutations was 8 per scFv, with an
average of 2.6 per VH, 4.1 per VL and 1.1 in the linker region.
ScFv HT186-D11 had four mutations in VH and three mutations
in VL.
Humanness score [61] and germinality index [62] were
analysed for the variable regions of the scFvs (table 6). Both
parameters were slightly reduced by the affinity maturation
process.
Analysis of the scFv sequences with NetNGlyc 1.0 Server
(http://www.cbs.dtu.dk/services/NetNGlyc/) revealed one poten-
tial N-glycosylation site in the CDR2 of VL of HT200-3A-C1
and HT220-M-D1. These clones were excluded from further
experiments.
Production and comparision of IgGs and scFv-Fc fusion
proteins
Three affinity matured antibodies which are stable and did not
show any potential N-glycosylation sites (HT186-D11, HT186-B7,
HT186-G2) were recloned as human IgG and scFv-Fc fusion
proteins, produced in HEK293T cells and purified by protein A
affinity chromatography.
These antibodies and the hHMFG1 IgG control were compared
by titration ELISA using the 32 amino acid MUC1 peptide
(figure 10A). The hHMFG1 showed weaker binding to MUC1
when compared to the three HT186 antibodies. The scFv-Fc
variants bound slightly better than the IgG variants of HT186-D11
and HT186-B7. In case of HT186-G2, the recloning into the IgG
format led to an affinity decrease of about 10fold. The binding to
Figure 2. IIB6 binding to MUC1. MUC1 negative fibroblast,
MUC1 positive T47D cells and MUC1 preparations (BMA) were
separated by 7.5% SDS-PAGE and Western-blotted. The blot was
stained with 5 mg/ml IIB6, mouse anti-his tag (1:1000) and goat anti-
mouse IgG (Fab specific) HRP conjugate (1:5000)
doi:10.1371/journal.pone.0015921.g002
Anti-MUC1 Antibody
PLoS ONE | www.plosone.org 4 January 2011 | Volume 6 | Issue 1 | e15921Figure 3. Cell stainings with purified scFv on different MUC1+ tumour cell lines and a MUC1 negative cell line (HEK293T) using FACS.
1 mg of purified scFvs were incubated on four different cell lines. The bound scFvs were detected with mouse anti-his6 tag IgG (1:50) (Roche, Penzberg,
Germany) and with goat anti-mouse IgG Fc specific FITC conjugate (1:200) (Sigma). White peak: detection antibodies only, grey peak: anti-MUC1 scFv.
The MFI is also given for the detection antibodies (upper row only, above the white peak), and for each scFv. 5000 cells were analysed per run.
doi:10.1371/journal.pone.0015921.g003
Anti-MUC1 Antibody
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IgG varants bound weaker than their scFv-Fc analog with HT186-
D11 showing the best binding to T47D cells, and huHMFG1 (only
analysed as IgG) showing the lowest binding to MUC1.
The IgG binding to tumour cell lines was analysed by FACS
(figure 11). No binding was observed on the control cell line
HEK293T (figure 11A). Only hHMFG1 bound to SKOV3
(figure 11B). HT186-D11, -B7 and hHMFG1 bound, nearly
Table 1. Affinity determination (kinetic) by SPR of anti-MUC1 scFvs to MUC1 peptide antigen.
scFv ka [1/M N s] kd [1/s] Rmax (theor.) KD [M]
fold increase with
respect to IIB6 X
2
IIB6* - - 41 3.1 N 10
-7 -1 . 2
HT186-B7 3.5 N 10
4 2.1 N 10
25 519 1.3 N 10
29 2386 7.0
HT186-D11 3.8 N 10
4 7.2 N 10
25 519 5.7 N 10
210 5446 4.8
HT186-G2 7.2 N 10
4 1.0 N 10
25 512 1.0 N 10
29 3106 36.7
HT200-3A-C1 4.9 N 10
4 1.0 N 10
24 211 2.1 N 10
29 1486 4.3
HT220-M-D1 2.9 N 10
4 1.1 N 10
24 200 3.7 N 10
29 846 2.3
HT220-M-G8 5.0 N 10
4 2.2 N 10
24 80 4.4 N 10
29 706 1.5
*Kinetic evaluation was not possible for IIB6, steady-state model was used instead.
doi:10.1371/journal.pone.0015921.t001
Figure 4. Stability analysis of the anti-MUC1 scFvs. A Purified scFvs (5 mgm L
21) were incubated in PBS up to 30 days at 37uC. After different
incubation times, binding to MUC1 peptide was tested by ELISA. For each scFv, the absolute ELISA signal at t=0 was set as 100%, all other signals
refer to this value. Each well was coated with 50 mg MUC1 peptide antigen (32mer cys). Detection was performed using a mouse-anti-c-myc-IgG
(9E10) (1:500) and a goat-anti-mouse-IgG (Fab spec.) HRP conjugate (1:10,000). B The same stability assay was performed with human serum instead
of PBS.
doi:10.1371/journal.pone.0015921.g004
Anti-MUC1 Antibody
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showed a weaker binding (figure 11C).
In vivo activity of HT186-D11 studied on xenograft
models
The affinity matured anti-MUC1 binder HT186-D11 was
analysed in MCF-7 and NIH:OVCAR-3 xenograft mouse models
(figure 12). At the dose of 15 mg/kg of Taxol (paclitaxel) used as a
positive control, the MCF-7 tumour cell growth was delayed in
comparison to the untreated group (figure 12A). However, no
tumour growth delay was observed in the HT186-D11 treated
group alone or in combination with 7.5 mg/kg Taxol.
The survival rate was analysed in an intraperitoneal NIH:OV-
CAR-3 xenograft mouse model. Here, as previously observed in
the sub cutan MCF-7 xenografts the optimal dose of 15 mg/kg
Taxol resulted in an increase of survival rate in comparison to the
untreated group (figure 12B). However, no survival increase was
observed in the HT186-D11 treated-group alone or in combina-
tion with 7,5 mg/kg Taxol.
ADDC
The antibodies huHMFG1, HT186-B7, -D11 and -G2 were
analysed for antibody dependent cell cytotoxicity (ADCC) on
MUC1 positive MCF-7 and OVCAR3 cells. Here, non of the
analysed antibodies showed ADCC activity on MCF-7 cells. A
slight ADCC activity was observed on OVCAR3 cells compared
to the antibody independent cytotoxicity (AICC) in which
huHMFG1 showed the highest ADCC, followed by HT186-G2
(data not shown).
Internalisation assays
The internalisation at 4uC and 37uC for 1 h of huHMFG1 and
HT186-D11 into MCF-7 cells was analysed by flow cytometry
(figure 13). The percentage of MUC1 positive cells decreased from
75% (4uC) to 29% (37uC) in case of huHMFG1 and 68% to 23%
for HT186-D11. Therefore, about 45% of the antibodies were
internalised at 37uC according to the percentage of MUC1
positive surface stained cells.
Discussion
MUC1 is a promising target for breast cancer tumour therapy
since it is overexpressed and underglycosylated on 90% of breast
cancer and also on other cancer types [21,52].
Figure 5. Breast cancer tissue immunohistochemistry stainings. MUC1 was stained with IIB6 (5 mg/ml), mouse anti-his (1:1000) (Qiagen,
Hilden), rabbit-anti-mouse antibody (1:250) and detected by Peroxidase complex after Thyramine amplification (1:200).
doi:10.1371/journal.pone.0015921.g005
Table 2. Analysis of the IHC stainings with mamma carcinom
tissues.
intensity of staining total frequency percentage
negative 40 17,5%
membrane low 5 2,2%
membrane medium 18 7,9%
membrane high 9 3,9%
plasma low 43 18,9%
plasma medium 59 25,9%
plasma high 12 5,3%
both medium 15 6,6%
both high 27 11,8%
total 228 100,0%
doi:10.1371/journal.pone.0015921.t002
Anti-MUC1 Antibody
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tissue positive staining negative staining comments
adipose tissue 0 8
adrenal gland cortex 0 8
adrenal gland medulla 0 8
bone marrow 0 8
cerebellum 0 8
cerebrum 0 8
cervix 0 8
colon 0 8
duodenum* 3 5
endometrium 4 4 gland eptihel, cytogenic stroma negativ
gall bladder 0 8
heart 0 8
ileum 0 8
jejunum 0 8
kidney cortex 0 8
kidney medulla 0 8
liver 0 8
lung 0 8
lymph knots 0 8
myometrium 0 8
oesophagus squam. epithelium 0 8
ovar 0 8
pancreas 2 6 few small cell clusters (.5%)
paranasal sinus 4 4 weak, cytoplasma, in gland epithelium
parathyroid 8 0 diffuse or single cell
parotis 8 0 gland aercini negativ, only intercalated duct
placenta 1 7 synzytiotrophoblasts positiv
prostata 0 8
sceletal muscles 0 8
smooth muscles 0 8
spleen 0 8
stomach 0 8
synovia 0 8
testicles 0 8
thymus 0 8
thyroid gland* 2 6 single cells
tonsils 0 8 few sinus histocytes
ureter 0 8
total 32 272 =304 tissue slides
Eight slides of each tissue type were analysed.
*suspected reaction of the detection system with endogenous biotin.
doi:10.1371/journal.pone.0015921.t003
Table 4. Overview about the constructed IIB6 mutation libraries.
Library
sequential error prone
PCRs Trans-formations theoretical complexicity % full size inserts
avg. point mutation rate
per scFv gene
A 4 1 7.4610
7 45 <20
B 7 4 1.8610
8 25 <30
doi:10.1371/journal.pone.0015921.t004
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immune antibody phage display library constructed from MUC1
peptide vaccinated patients, a strategy which has been tested for
different MUC1 positive cancers [63–65]. For this project,
immune antibody gene libraries were used instead of naive
libraries because this strategy is supposed to yield binders with a
higher affinity [8,66,60].
The IHC studies showed that 80% of the breast cancer tumour
tissues are detected by scFv IIB6. This is in accordance with the
IHC studies performed with humanised anti-MUC1 binder
hPankoMab [52]. Only very few nonmalignant tissues were stained
with scFv IIB6. A staining of normal endometrium and pancreas
was also observed for the anti-MUC1 binder PH1, whereas
parathyroid was not stained by PH1 [55]. This very high specificity
is an interesting observation, in light of the fact that the recognised
epitope comprises a stretch of just four amino acid side chains.
Although the monovalent affinity of scFv IIB6 of 3610
27 Mi s
relatively low in comparison to other scFvs derived from immune
libraries, i.e. with other specificities [67,8,59,60], it is higher than
the affinity of MUC1 binder PH1, which has an affinity of
1.4610
26 M [55]. Interestingly, the scFvs developed here showed
good binding to the breast cancer cell line T47D and ovarian
cancer cell line SKOV3, but no binding to the second breast
cancer cell line MCF-7.
Because of the low affinity, scFv IIB6 was affinity and stability
matured. Different maturation strategies are described for affinity
improvements of antibody fragments. Introducing random point
mutations into the antibody gene, either by error prone PCR [68]
or by E. coli mutator strains [69] followed by a phage display based
selection under stringent conditions, allows the selection for new
variants bearing improved biochemical properties. In this work,
two kinds of error prone PCR libraries were generated and the
screening was performed as off-rate selective pannings in MTPs, in
solution and in solution with competition. Improved variants were
selected using all three panning methods. Despite the small
number of examples, it appears that the antibodies derived from
the off-rate panning showed the best anti-MUC1 binding
properties in different subsequent assays.
The affinity of the affinity matured scFv HT186-D11 was
increased about 500-fold compared to the initial scFv IIB6. In the
literature, affinity maturations using error prone PCR or mutator
strains achieved improvement from 2 to 6000 fold [69–71]. Other
technologies successfully used for affinity maturation are random
mutagenesis followed by ribosome display [72], random mutagen-
esis followed by yeast display [73], chainshufflingfollowed by phage
display [74] or by a rational design-based approach [75]. To date,
affinities to MUC1 in the subnanomolar range are only described
for murine IgGs binding to tandem repeats of MUC1 or MUC1-
presenting cells. The apparent affinites shown for PankoMab and
HMFG1/huHMFG1 are in the range of 0.9-7610
29 M or 0.4–
1.9610
28 M, respectively, depending on the cell line used for
analysis [45,76]. A monovalent and apparent affinity is given for the
human anti-MUC1 binder PH1. Here, the monovalent affinity of
the Fab fragment is 1.4610
26 M and the corresponding apparent
affinityis8.7610
29 M [55].Hence,HT186-D11 isthehumananti-
MUC1 binder with the highest described affinity.
The identified Epitope RPAP is part of the hydrophilic
sequence PDTRPAP, which is described to be the most important
immunogenic sequence of the VNTR region of MUC1 [77,53].
Analysis with the murine antibody C595 which also binds to
RPAP showed, that the first and the last amino acid of this antigen
were essential for antigen binding [78].
We found out that nearly all affinity matured binders also had a
lower tendency to dimerise. The dimerisation tendency correlated
with the stability of the binder. The binders with the lowest
stability showed the highest dimerisation tendency. Some of the
Table 5. Single antibody clones selected by three different
panning methods for further biochemical charactisation.
Clone Panning method Competitor
HT186-B7 off rate -
HT186-D2 off rate -
HT186-D11 off rate -
HT186-D8 off rate -
HT186-G2 off rate -
HT200-3A-C1 in solution -
HT200-3A-E2 in solution -
HT200-3B-E10 in solution -
HT220-M-C6 in solution + competition 10006excess MUC1
peptide
HT220-M-D1 in solution + competition 10006excess MUC1
peptide
HT220-M-G8 in solution + competition 10006excess MUC1
peptide
HT220-D-G9 in solution + competition 10006excess soluble
HT186-D11 scFv
HT220-D-H11 in solution + competition 10006excess soluble
HT186-D11 scFv
doi:10.1371/journal.pone.0015921.t005
Figure 6. Rating of the affinity matured anti-MUC1 scFvs. Surface plasmon resonance using 90 mL of 1/10 diluted culture supernatants of the
scFvs, injected with a flow rate of 30 mL/min.
doi:10.1371/journal.pone.0015921.g006
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equivalent to 1–2 years storage at 4uC and about half a year at RT
[79]. To our knowledge, this is the first direct observation of a
correlation of the dimerisation tendency of scFvs with the stability
determined by a long term storage assay. To date, dimerisation
tendencies were correlated with the stability determined by
differential scanning calorimetry [80] or the effects of parameters
like pH, temperature or scFv concentration [81–83].
The three best binders were recloned into the scFv-Fc and IgG
format and analysed by titration ELISA on MUC1 and FACS
analysis using T47D. In the titration ELISA, two of the three scFv-
Fc fusion proteins were comparable with the corresponding IgGs.
The about 10fold decrease in affinity of the HT186-G2 after
conversion is influenced by 8 amino acid differences in the VH and
4 amino acid differences in the VL sequence compared to HT186-
D11. In the FACS analysis, all IgG variants showed a lower cell
binding compared to the scFv-Fc fusion protein.
T h er e a s o nf o rt h ed i f f e r e n c eo fs c F v - F ca n dt h ec o r r e s p o n d i n gI g G
regarding the affinity could be different VH to VL angles or other
issues related to the particular IIB6 framework. When converting
antibodies from the scFv format to the Fab format and vice versa, the
apparent affinities were maintained or decreased [84–86].
The cell stainings of SKOV3 and MCF-7 were also repeated
with the IgGs. Here, only huHMFG1 bound to SKOV3. On
MCF-7, two of three affinity matured binders and huHMFG1
bound. The binding of all antibodies on T47D cells was much
stronger than on MCF-7 cells. huHMFG1 binds the epitope
PDTR whereas HT186-D11 binds to RPAP. Antibodies are
binding different to different MUC1 positive cell lines [55].
The in vitro experiments showed no significant ADCC using
established MUC1 positive cell lines MCF-7 or OVCAR3. In the
in vivo experiments no decreased tumour growth or increased mice
survival rate using MCF-7 or OVCAR3 xenograft models was
observed. Recently, a clinical phage 2 trial of huHMFG1 by
Antisoma (http://clinicaltrials.gov/ct2/show/NCT00770354) was
discontinued because ‘‘the trial would be very unlikely to give
sufficiently positive efficacy findings’’ (http://www.antisoma.com/
asm/media/press/pr2009/2009-08-07/). To reveal the reasons
for the failed xenograft experiments, ADCC was analysed in vitro
using MCF-7 and OVCAR3 target cells. Here, no significant
ADCC was detected for both huHMFG1 and HT186-D11.
Since it is known that anti-MUC1 aptamers [87] and antibodies
binding to different MUC1 epitopes will be internalised
[55,88,89,50,51], the internalisation of huHMFG1 and HT186-
D11 was analysed using MCF-7 cells. Both antibodies were
internalised by this MUC1 tumour cell line which can explain the
low efficacy observed in vitro and in vivo. On the other hand, the
internalisation of MUC1 specific antibodies by tumour cells allows
other therapeutic approaches including the delivery of toxic
compounds into the tumour cells, e.g. antibody drug conjugates or
immunotoxins [90–92]. These concepts were tested e.g. using an
anti-prostate-specific membrane antigen (PSMA) antibody cou-
pled to ricin [93], or saporin [94], an anti-HER2 antibody coupled
to Pseudomonas exotoxin A [95] or an anti-human asialoglyco-
protein using the same toxin [96]. The employment of
heterologous toxins raises concerns of unspecific toxicity and
immunogenicity [97]. Here, the fusion of human antibodies with a
human RNase may overcome these issues. The so-called immuno
RNase approach was already demonstrated for an anti-CD30
antibody fused to human RNase1 [98].
In conclusion, our study provides another example how phage
display based in vitro evolution was able to create an antibody with
superior biochemical properties, exquisite specificity on tissue, and
good product properties, by reducing aggregation and dramati-
cally improve stability in serum. However, it also emphasises that
functional in vivo studies should be done as soon as ever possible in
the development of any therapeutic lead candidate.
Materials and Methods
Ethics Statement
Immunisation experiments: Human blood cell RNA was
prepared from diagnostic blood sample waste obtained from a
study (‘‘klinischer Heilversuch’’) on MUC1 immunisation in the
Woman’s Clinic of the University of Heidelberg. The materials
were obtained anonymously. Following the legal standards for a
‘‘klinischer Heilversuch’’ valid at the time of sample preparation
(Oct. 2000), neither a statement of the Ethical commission nor a
patient consent was required for additional experimental work on
anonymised samples from waste materials.
Mouse experiments: The animal care unit is authorized by the
French ministries of Agriculture and Research (Agreement
Figure 7. Ranking of the affinity matured anti-MUC1 scFs by antigen titration ELISA. A dilution series of scFvs was used for MUC1
detection. The bound scFvs were detected with mouse anti-myc (1:1,000) and goat anti-mouse IgG (Fab specific) HRP conjugate (1:10,000) (Sigma,
Mu ¨nchen, Germany).
doi:10.1371/journal.pone.0015921.g007
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to the European ethical guidelines of animal experimentation
(Principe d’e ´thique de l’expe ´rimentation animale. Directive Nu86/
609 CEE du 24 Nov. 1986) and the English guidelines for welfare
of animals in experimental neoplasia (Workman P et al. UKCCCR
guideline. Br J Cancer 1998, 77:1–10). All procedures with
animals were submitted to the Animal Care and Use Committee
of Pharmacy and Medicine University (Dijon).
Construction of an immune antibody phage display
library
The immune library was constructed from peripheral blood B
lymphocytes from mamma carcinoma patients which were
vaccinated with a VNTR MUC1 Peptide (APDT(GalNAc)R-
PAPGSTAPPA). The library was constructed using the vector
pSEX81 [57] and a human primer set [56] according to [99].
Selection of anti-MUC1 binders
The panning and screening was performed according to [100].
Breast Mucin Antigen (BMA) was purified by affinity chromatog-
raphy from cells of the human breast cancer cell line T47D using
mouse mAb BM7. Panning rounds were performed on 10 mg
MUC1 (BMA) and a MUC1 glycopeptide (APDT(GalNAC)R-
PAPGSTAPPA-C).
SDS-PAGE and immunoblot
Samples of total cell lysates were run on a reducing 7.5% SDS-
PAGE and electroblotted onto nitrocellulose filter. The filter was
Figure 8. Epitope mapping. A The epitope mapping membrane (15mer oligopeptide, 1 amino acid overlap) was stained with 30 mg scFvs. The
bound scFvs were detected with mouse anti-c-myc IgG (9E10) (1:500) and a goat anti-mouse IgG (Fab spec.) AP conjugate (1:2000). NWS = detection
antibodies only. B Sequence overview. Amino acid sequences of the single spots on the nitrocellulose membrane. Immunostained spots were
marked in grey. Amino acids forming the minimal epitope are given in bold. The sequence of one complete VNTR repetitive region is underlined.
doi:10.1371/journal.pone.0015921.g008
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staining was performed using 5 mg/mL IIB6, followed by detection of
the His-tag with mouse anti-(His)5 mAb (Qiagen, Hilden, Germany)
(1:1000) and goat-anti-mouse IgG HRP conjugated (Dianova,
Hamburg, Germany) (1:5000). The detection was performed using
NovaRed Substrate Kit (Vector, Burlingame, USA).
Figure 9. Size exclusion chromatography analysis to analyse the dimerisation tendency of the anti-MUC1 scFvs. 80 mg purified scFv
fragments were separated on a Superdex200 10/300 column using PBS as running buffer with a flow rate of 0.5 mL min
21. The UV-absorption (A280)
was drawn against the retention volume.
doi:10.1371/journal.pone.0015921.g009
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Immunohistochemical staining were done on formalin-fixed
and paraffin embedded human breast samples and 304 healthy
tissues from 38 different organs/locations according to [101]. All
samples were retrieved from the archives of the Institute for
Pathology, Medizinische Hochschule Hannover. In brief, slides
were deparaffinized in xylene and rehydrated in graded alcohol.
Heat induced epitope retrieval using the microwave technique
(citrate buffer pH 6.0, 20 min at 100uC) was followed by blocking
of endogenous peroxidase with 3% H2O2 as well as endogenous
biotin by an Avidin/Biotin-blocking Kit (Vector Laboratories,
Burlingame, Ca, USA).
The primary scFv IIB6 was incubated (5 mg/ml) overnight at
4uC. The detection was performed using mouse anti-his (1:1000)
(Qiagen, Hilden), followed by biotinylated secondary rabbit-anti-
mouse antibody (1:250) (Zymed Laboratories, San Francisco, CA,
USA) at room temperature and detected by a sensitive Peroxidase
complex after Thyramine amplification (1:200) (NenLifeScience,
Boston, MA, USA). DAB served as substrate and hematoxylin for
counterstaining.
Construction of the mutation libraries
1 ng template DNA of the initial anti-MUC1 binder IIB6 was
amplified in a volume of 25 mL using a random mutagenesis PCR
kit (GeneMorphII, Stratagene) and 0.2 mM of the oligonucleotide
primer HT-IIB6-Aff_fwd (59 tgctggcagctcagccggccatgg 39) and
HT-IIB6-AFF_rev (59 tgatggtgatgatgatgagcggccgc 39)) for 35
cycles (94uC6 0s ,6 5 uC6 0s ,7 2 uC 70s) followed by a 10 min
final synthesis step. The PCR products were purified by agarose
gel electrophoresis using the Nucleospin Extract 2 Kit (Macherey-
Nagel, Du ¨ren). This step was repeated three times for library ‘‘A’’.
The PCR products were purifed and cloned into the phagemid
pHAL14 using the restriction sites NcoI and NotI.
The library ‘‘B’’ was cloned in the same way as library ‘‘A’’ with
following modifications. The random mutagenesis was performed
by nested PCR using sequential three sets of primers: MHLacZ-
Pro_f (59 ggctcgtatgttgtgtgg 39)/HT-gIII-Beginn1-rev (59 taaa-
caactttcaacagtttcagct 39), MKpelB_f (59 gcctacggcagccgctgg 39)/
MKmyc_r (59 gatcctcttctgagatgag 39) and HT-IIB6-Aff_fwd/HT-
IIB6-AFF_rev. In total, the random mutagenesis PCRs were
performed seven times.
The libraries were packaged using M13K07 as described by
[102].
Selection (panning) of affinity matured scFvs
The off rate selection was performed as follows: MUC1 15 aa
peptide with cystein (APDTRPAPGSTAPPA-C) was coated over
night in different amounts (100 ng, 10 ng, 1 ng) using sodium
carbonate buffer pH 9.7 (35 mM NaHCO3, 15 mM NaHCO3)
into Nunc Maxisorp stripes (Nunc, Langenselbold, Germany),
followed by blocking with 1% (w/v) BSA in M-PBST (phosphate
buffered saline [103]+0,1% Tween 20+2% skim milk powder) for
1 h at RT. Afterwards, the wells were washed with PBST using an
ELISA washer (TECAN Columbus Pro). About 4610
10 phage
particles of the mutation library ‘‘A’’ were incubated into each well
for 3 h in M-PBST followed by 306stringent bottom wash using
an ELISA washer. Afterwards the stripes were incubated for one
week in 2 L PBS under gentle shaking at 4uC. The stripes were
washed 206as described above and incubated again for one week
in 1 L PBS at 4uC and gentle shaking followed by 206washing.
Afterwards the stripes were incubated for the third week as
described above. The wells were washed 36 with the standard
washing protocol and the remaining scFv-phage were eluted using
Table 6. Germinality index and humanness (Z-score) for the
variable region of the anti-MUC1 scFvs.
VH VL
germinality
[%] Z-score
germinality
[%] Z-score
IIB6 85.8 20.97 98.1 0.63
HT186-B7 85.8 20.96 93.5 0.20
HT186-D11 82.5 21.00 95.3 0.55
HT186-G2 82.5 21.10 96.3 0.43
HT200-3A-C1 85.8 20.97 93.5 0.44
HT220-M-D1 83.3 21.18 90.1 20.02
HT220-M-G8 82.5 21.11 95.3 0.31
Germinality index is calculated by aligning the amino acid sequence of the
variable region to the next human germline sequence [62]. Z-scores were
calculated using the SHAB web interface (http://www.bioinf.org.uk/abs/shab/)
[61].
doi:10.1371/journal.pone.0015921.t006
Figure 10. A Antigen ELISA using anti-MUC1 scFv-Fc fusion
proteins and anti-MUC1 IgGs. 50 mg MUC1 peptide antigen (32mer
cys) were immobilised in each well. Antibodies were incubated in
different concentrations. A goat-anti-human-IgG (Fc spec.) HRP
conjugate (1:10,000) was used for detection of bound anti-MUC1
antibodies. B Flow cytometry analysis of anti-MUC1 IgG and scFv-Fc
antibodies titrated on T47D. Antibodies were detected with goat anti-
human IgG Alexa488 conjungate (1:200) (Invitrogen, Darmstadt,
Germany). 10000 cells were analysed per run. MFI was plotted against
the antibody concentration.
doi:10.1371/journal.pone.0015921.g010
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Blue MRF’ (Stratagene, Amsterdam) were grown up to O.D.600
0.4–0.5. 50 mL bacteria were infected with the eluted antibody
phage, plated on 26TY agar plates [103] +100 mg/mL ampicilin
+100 mM glucose and incubated over night at 37uC.
The panning in solution was performed as follows: 50 mL
streptavidin beads (Dynabeads M280, Dynal, Oslo) were incubat-
ed with M-PBST for 1 h. All incubation steps were performed in
an overhead shaker. The beads were captured using a magnetic
separator (Dynal MPC, Dynal, Oslo). The blocked beads were
incubated with about 1610
13 phage particles of mutation library
‘‘B’’ for 30 min to deplete bead binders. The supernatant with the
residual library was incubated with 60 nM biotinylated 32 aa
MUC1 peptide (Biotin-bA-bA-APDTRPAPGSTAPPAHGVT-
SAPDTRPAPGSTA) in M-PBST with 2% BSA (bovine serum
albumin) for 1 h at RT followed by an incubation with about
7610
7 blocked streptavidin beads for 15 min. The beads with the
bound antibody phage were captured by pull down in a magnetic
separator. The beads were washed 20 times with PBS. Elution of
the bound scFv phage particles with trypsin and reamplification of
the scFv phage were done as described for panning in MTPs by
Hust et al. 2007 [104]. In total three panning rounds were
performed.
The panning in solution with competion was performed as
follows. The procedure was analogous to the panning in solution
with the following modifications. After incubation of the mutation
library with biotinylated MUC1 peptide, an excess of the
competitor, 1 mM non-biotinylated MUC1 peptide or soluble
MUC1 binder, was added (10006 excess) and incubated for an
additional week at 4uC.
Production of scFvs in microtitre plates (MTPs)
For the identification of monoclonal binders, colonies from the
titre plates of the eluted phage particles after panning were picked
and soluble scFvs were produced in microtitre plates as described
before [105].
Enzyme linked immunosorbent assay (ELISA)
For anti-MUC1 ELISA, MUC1 32 aa peptide with a C-
terminal cystein (APDTRPAPGSTAPPAHGVTSAPDTRPAPG-
STA-C) was coated to 96 well microtitre plates (Maxisorp, Nunc)
in PBS over night at 4uC. After coating, the wells were washed
three times with PBST and blocked with 2% (w/v) skim milk
powder in PBST (2% M-PBST) for 1.5 h at RT, followed by three
washing steps with PBST. For the antigen ELISA soluble scFvs,
scFv-Fc fusion proteins or IgG were diluted in 100 mL2 %M -
PBST and incubated in the MUC1 coated plates for 1.5 h at RT
followed by three PBST washing cycles. Bound scFvs were
detected with the murine mAb 9E10 which recognises the C-
terminal c-myc tag and a goat anti-mouse serum conjugated with
horseradish peroxidase (HRP) (Sigma; 1:10,000). IgG and scFv-Fc
fusion proteins were detected using goat anti-human Fc specific
serum conjugated to HRP (Sigma; 1:20.000). The visualisation
was performed with TMB (3,39,5,59-tetramethylbenzidine) as
substrate and staining reaction was stopped by adding 100 ml
1 N sulphuric acid. Absorbance at 450 nm was measured by using
a SUNRISE
TM microtitre plate reader (Tecan, Crailsheim,
Germany).
Surface Plasmon Resonance (SPR)
Surface plasmon resonance was performed using Biacore 2000
according to the Biacore manual. Briefly, about 50 RU
recombinant MUC1 15 aa with cysteine peptide (APDTRPAPG-
STAPPA-C) were coupled in 10 mM sodium acetate buffer
Figure 11. Flow cytometry analysis of anti-MUC1 IgG and scFv-
Fc antibodies on different tumour cell lines HEK293T (A),
SKOV3 (B) and MCF-7 (C). Different anti-MUC1 antibody concentra-
tions were incubated on two different MUC1 positive cell lines and one
MUC1 negative cell line. Detection was performed as given for figure 8B.
doi:10.1371/journal.pone.0015921.g011
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chemistry, followed by PDEA in 80 mM borate buffer. For
reference, 50 RU of a control peptide were coupled in 10 mM
sodium acetate buffer pH 4.5. Remaining active groups were
saturated with 50 mM L-cysteine. Serial dilutions of scFv (0 nM –
400 nM) were measured at a flow rate of 50 mL/min. The chip
Figure 12. Activity studies performed in xenograft models. (A) Mean tumour volume curves observed in the MCF model. Starting on day 27,
mice were IP injected with irrelevant antibody LFB-R297 or HT186-D11 at 10 mg/kg weekly and for a total of 4 weeks. These treatments were
performed alone or in combination with IV injections of Taxol at 7.5 mg/kg injected once every week for 3 consecutive weeks. (B) Survival curves
observed in the NIH:OVCAR-3 model. Starting on day 13, mice were IP injected with irrelevant antibody LFB-R297 or HT186-D11 at 10 mg/kg weekly
and for a total of 4 weeks. These treatments were performed alone or in combination with IV injections of Taxol at 7.5 mg/kg injected once every
week for 3 consecutive weeks.
doi:10.1371/journal.pone.0015921.g012
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was performed using 1:1 Langmuir separate fitting algorithm of
the Biaevalution software.
Production of scFvs in E. coli
For production of scFvs in E. coli, scFvs were recloned into the
vector pOPE101-XP according to [105].
The affinity matured scFvs were produced in shake flasks
according to [106] with modifications. Briefly, 300 mL 26TY
[103] +100 mg/mL glucose +100 mg/mL ampicillin were inocu-
lated with an over night culture to O.D.600<0.15 and cultured at
37uC and 250 rpm. The induction was started by adjusting to
50 mM IPTG at O.D.600=0.9 and the cells were cultivated at
25uC and 250 rpm for 3h. Bacteria were harvested by centrifu-
gation for 5 min at 42006g at RT. Pellets were resuspended in
30 mL ice cold PE buffer, pH 8 (500 mM sucrose, 100 mM Tris,
1 mM EDTA) and incubated for 20 min on ice, interrupted by
short vortexing every 5 min. Subsequently the bacteria were
pelleted for 30 min at 30000 xg at 4uC. The supernatant
(periplasmic fraction) was stored at 220uC. The pellet was
resuspended in 30 mL ice-cold dH2O and incubated for 20 min
on ice, interrupted by short vortexing every 5 min. Spheroblasts
were pelleted for 30 min at 300006g and 4uC. The supernatant
(osmotic shock preparation) was stored at 220uC.
Epitope mapping
A series of 20 peptides (15mers overlapping by 14 amino acid
residues) representing the entire VNTR sequence of human
MUC1 were synthesized as an array on amino-cellulose
membrane by SPOT-synthesis [107,108]. This membrane-bound
peptide array was probed with scFv antibody fragments as
described above for the immunoblot except that MTT/BCIP
[100 mL 1 M MgCl2;8 0 mL BCIP (15 g/L in DMF); 120 mL
MTT [3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazoliumbro-
mide] (50g/L in 70% DMF +30% H2O2) in 20 mL CBS (8 g/L
NaCl, 0.2 g/L KCl, 2.08 g/L citrate, pH 7.0)] was used for
staining.
Size exclusion chromatography
Size exclusion chromatography was performed using Super-
dex200 10/300 GL column (GE Healthcare) on an A ¨KTA purifier
system (GE Healthcare). 100 mL of each sample were injected and
separated by using PBS as running buffer with a flow rate of
0.5 mL/min. A280 was plotted against the retention volume to
identify the different antibody fragments, in comparison to a set of
marker proteins analysed in separate runs.
Stability assay
The stability assay was performed according to [60]. Briefly,
scFvs were aliquoted as triplicates in 100 mL( 5mg/mL in PBS or
human serum) in 2 mL microtubes (Sarstedt, Nu ¨rnbrecht,
Germany) and stored at 280uC. Every three days and every day
for the last two samples, an aliquot was thawed and transferred
into a 37uC incubator. All samples were analysed at the same day
in the same antigen ELISA using MUC1 32mer Cys peptide as
antigen bound to microtitre plates (Nunc). A total of 80 mL of the
scFv solutions was analysed by antigen ELISA.
Flow cytometry
Tumour cells were cultured on poly-L-lysine coated 10 cm
diameter tissue culture plates at 37uC and 7% CO2 using media
specific for the cell lines. The cells were harvested at 70%
confluence. Therefore, the cells were washed with 10 mL PBS and
afterwards detached using 1 mL trypsin solution (10 mg/L trypsin
in PBS). The cells were centrifuged at 10006g for 5 min and
resupended in 3 mL FACS buffer (2% (v/v) fetal calf serum,
2 mM EDTA in PBS) with the anti-MUC1 scFv, scFv-Fc or IgG
on ice for 1 h. The cells were centrifuged as above, resupended in
3 mL FACS buffer, centrifuged again in resuspended again in
FACS buffer with mouse anti-his6 tag (1:50) (Roche, Penzberg,
Germany) for scFv staining or goat anti-human IgG Alexa488
conjugated (1:200) (Invitrogen) for scFv-Fc or IgG staining on ice
for 1 h. For scFv staining the cells were washed again and
resuspended in FACS buffer with goat anti-mouse IgG FITC
conjugated (1:200) (Sigma, Mu ¨nchen) on ice for 1h. Finaly, cells
were washed, resuspended in 500 mL FACS buffer and analysed
by flow cytometry using a FC500 with two lasers (488 nm and
633 nm, Beckman Coulter, Germany). For each sample 5000
(scFv) or 10000 (scFv-Fc, IgG) events were measured and data
were analysed using CXP analysis software (Beckman Coulter).
Production of IgG and scFv-Fc fusion proteins in
mammalian cells
The scFvs were recloned into the scFv-Fc format using the vector
pCMX2.5-hIgG1-Fc-XP according to [5].
Genes encoding VH and VL of hHMFG1, HT186-B7, -D11 and
-G2 were orderd as synthetic genes with codon optimisation for rat
(Genscript, Piscataway, NJ, USA). The mammalian expression
vector CHK622-08 was modified by replacing the C kappa with C
lambda derived from the vector CHL558-0. VH was cloned
between ApaI and NheI and VL was cloned between SpeIa n dDraIII.
All vector constructs were checked by DNA sequencing.
Xenograft experiments
Antitumour activity of HT186-D11 was evaluated on two
xenograft models. The models consisted of female Balb/c Nude
mice subcutaneously injected with the MCF-7 mammary human
tumour cell line or intraperitoneally injected with the NIH:OV-
CAR-3 ovary human tumour cell line. In the latter model, the cell
line was amplified in vivo in SCID mice and ascites were collected
and injected into Balb/c Nude mice.
Figure 13. Internalisation of anti-MUC1 HT186-D11 and
huHMFG1 IgGs. Internalisation was analysed by incubation of MCF-
7 cells with anti-MUC1 antibodies at 37uC or on ice (on ice or 4uC,
should be consistent throughout the paper) for 1h. Remaining cell
surface-associated mAbs were detected by staining with PE-conjugated
mouse anti-human IgG mab.
doi:10.1371/journal.pone.0015921.g013
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of 4 weeks injected by the intraperitoneal route. Antibodies
recognising human CD20 (LFB-R509) and D (LFB-R297)
antigens were used as controls. Treatment started on day 27 in
the MCF-7 model and on day 13 in the NIH-OVCAR-3 model.
Antibodies were administered alone or in combination with Taxol
(paclitaxel) at 7.5 mg/kg weekly for a total of 3 weeks and injected
by the intravenous route. Two groups treated with Taxol only
administered at 7.5 and 15 mg/kg were used as a control for the
chemotherapy treatment. Taxol treatment was administered 1 day
after the antibodies.
Antitumour efficacy was evaluated in the MCF-7 model by
measurement of the tumour volume and in the NIH:OVCAR-3
model by following the survival. The tumour volume was
calculated with the following formula where length corresponds
to the largest tumour diameter and width to the smallest tumour
diameter: TV=(length 6width
2)/2.
ADCC
The antibody-dependent cell-mediated cytotoxicity assays
(ADCC) were performed using purified human NK cells as
effector cells. Human NK cells were purified from the peripheral
blood of healthy donors by the negative depletion technique
developed by Miltenyi Biotec (Bergisch Gladbach, Germany).
The target cells, MCF-7 and OVCAR3, were mixed with NK
cells at an effector-target (E/T) ratio of 20/1 in the presence of
antibody dilutions. After 16 hours of incubation at 37uC and 7%
CO2, cytotoxicity was quantified using the cytotoxicity Detection
Kit (Roche Applied Sciences) based on lactate dehydrogenase
(LDH) released into the supernatants. Data was expressed as the
percent of lysis calculated according to the following formula:
% lysis~100 x ER{SR ðÞ = MR{SR ðÞ ,
where ER, SR, and MR represent experimental, spontaneous, and
maximum release, respectively. ADCC values were expressed as:
% ADCC~ % lysis in the presence ofmAb ðÞ {
% lysis without mAb ðÞ :
Internalisation Assay
To address the possibility that incubation at 37uC of anti-MUC-
1 mAb-labeled MUC-1+ cells results in mAb internalization, the
MCF-7 cells (2610
5 cells) were incubated with 10 mg/ml of anti-
MUC1 antibodies (huHMFG1 or HT186-D11) on ice for 1h.
After washing in cold PBS, 2% FCS, cells were separated in two
groups and incubated for 1 h at 4uC and 37uC, respectively. After
washing, the remaining cell surface-associated mAb was detected
by staining with PE-conjugated mouse anti-human IgG mab
(Beckman Coulter).
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